Get the Stockscreener App
64.02
1.74%
-1.02
Biomarin Pharmaceutical Inc stock is traded at $64.02, with a volume of 364.26K.
It is down -1.74% in the last 24 hours and down -4.04% over the past month.
See More
Previous Close:
$65.04
Open:
$64.7
24h Volume:
364.26K
Relative Volume:
0.22
Market Cap:
$13.13B
Revenue:
$2.75B
Net Income/Loss:
$322.29M
P/E Ratio:
83.28
EPS:
0.7687
Net Cash Flow:
$300.88M
1W Performance:
-1.50%
1M Performance:
-4.04%
6M Performance:
-16.36%
1Y Performance:
-30.85%
1-Day Range:
$63.56
$65.13
1-Week Range:
$63.56
$66.17
52-Week Range:
$61.15
$99.56
Biomarin Pharmaceutical Inc Stock (BMRN) Company Profile
Name
Biomarin Pharmaceutical Inc
Sector
Industry
Phone
(415) 506-6700
Address
105 DIGITAL DRIVE, NOVATO, CA
Compare BMRN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BMRN
Biomarin Pharmaceutical Inc
|
63.98 | 13.13B | 2.75B | 322.29M | 300.88M | 1.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
461.00 | 119.71B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 82.77B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
620.93 | 37.02B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.31 | 32.26B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.50 | 28.24B | 3.30B | -501.07M | 1.03B | -2.1146 |
Biomarin Pharmaceutical Inc Stock (BMRN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-30-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Aug-20-24 | Upgrade | Bernstein | Mkt Perform → Outperform |
| May-17-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-14-24 | Initiated | Evercore ISI | Outperform |
| Nov-15-23 | Initiated | Wells Fargo | Overweight |
| Oct-23-23 | Upgrade | Bernstein | Underperform → Mkt Perform |
| Sep-28-23 | Initiated | Raymond James | Mkt Perform |
| Sep-18-23 | Initiated | UBS | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Perform |
| Jul-05-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jun-14-23 | Resumed | Credit Suisse | Outperform |
| Mar-21-23 | Initiated | Bernstein | Underperform |
| Feb-22-23 | Downgrade | Oppenheimer | Outperform → Perform |
| Feb-21-23 | Initiated | Citigroup | Neutral |
| Jan-30-23 | Initiated | BMO Capital Markets | Market Perform |
| Jan-18-23 | Initiated | Canaccord Genuity | Hold |
| Oct-31-22 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-13-22 | Resumed | Wedbush | Neutral |
| Apr-25-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-22-21 | Upgrade | William Blair | Mkt Perform → Outperform |
| Oct-07-21 | Resumed | Jefferies | Buy |
| Sep-09-21 | Upgrade | Stifel | Hold → Buy |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Mar-04-21 | Resumed | Guggenheim | Buy |
| Mar-01-21 | Upgrade | Evercore ISI | In-line → Outperform |
| Aug-20-20 | Downgrade | Citigroup | Buy → Neutral |
| Aug-20-20 | Downgrade | William Blair | Outperform → Mkt Perform |
| Aug-19-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Aug-19-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Aug-19-20 | Downgrade | Stifel | Buy → Hold |
| Jul-08-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jul-06-20 | Reiterated | Citigroup | Buy |
| Jan-28-20 | Initiated | BMO Capital Markets | Market Perform |
| Jan-27-20 | Initiated | BMO Capital Markets | Market Perform |
| Jan-24-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-27-19 | Upgrade | Barclays | Equal Weight → Overweight |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| May-23-19 | Resumed | Citigroup | Buy |
| Apr-09-19 | Resumed | Raymond James | Outperform |
| Jan-02-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Dec-14-18 | Initiated | Wolfe Research | Outperform |
| Oct-01-18 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-07-18 | Reiterated | Stifel | Buy |
| Aug-03-18 | Reiterated | Stifel | Buy |
View All
Biomarin Pharmaceutical Inc Stock (BMRN) Latest News
Rockefeller Capital Management L.P. Boosts Stock Holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares Sold by BNP Paribas Financial Markets - MarketBeat
PDT Partners LLC Invests $2.32 Million in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
Erste Asset Management GmbH Buys New Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Stock Holdings Increased by Bellevue Group AG - MarketBeat
Vestal Point Capital LP Buys New Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares Acquired by Bridgewater Associates LP - MarketBeat
Why Is BioMarin (BMRN) Down 1.9% Since Last Earnings Report? - Yahoo Finance
FORA Capital LLC Acquires 16,926 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
14,376 Shares in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Acquired by Dynamic Technology Lab Private Ltd - MarketBeat
Why Is BioMarin Pharmaceutical Inc. (BMRN) Among the Worst Performing Healthcare Stocks in 2024? - Insider Monkey
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares Acquired by Charles Schwab Investment Management Inc. - MarketBeat
Can BioMarin Stock Live Up to Wall Street's High Expectations? - MSN
10 Worst Performing Healthcare Stocks in 2024 - Insider Monkey
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares Bought by Swedbank AB - MarketBeat
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
King Luther Capital Management Corp Buys New Shares in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
Connor Clark & Lunn Investment Management Ltd. Purchases Shares of 116,257 BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
Can BioMarin Stock Live Up to Wall Street’s High Expectations? - sharewise
Equities Analysts Set Expectations for BMRN FY2024 Earnings - MarketBeat
Why Is BioMarin Pharmaceutical Inc. (BMRN) Among the Worst Performing Biotech Stocks in 2024? - Yahoo Finance
Layoff Tracker: J&J, Merck Trimming Workforces in China - BioSpace
BioMarin: Challenges Mount, But Sale Rumors Make For A Risky 'Buy' Call (NASDAQ:BMRN) - Seeking Alpha
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value Stock - Yahoo Finance
Zacks Research Brokers Raise Earnings Estimates for BMRN - MarketBeat
Primecap Management Co. CA Acquires 77,350 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
Phenylketonuria Market size is ~700 USD million in 2023, asserts DelveInsight | Pharma Giants: PTC Therapeutics, Homology Medicines, Synlogic, BioMarin Pharmaceuticals - The Globe and Mail
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock - Yahoo Finance
EULAV Asset Management Grows Holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
DOJ reportedly subpoenas BioMarin over sponsored testing programs - MSN
Wolfe Research Initiates Coverage of BioMarin Pharmaceutical (BMRN) with Outperform Recommendation - MSN
Howe & Rusling Inc. Acquires 24,971 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
BioMarin Pharmaceutical Inc. (BMRN): Among the Best Genomics Stocks to Buy Right Now - Insider Monkey
Implied Volatility Surging for BioMarin Pharmaceutical (BMRN) Stock Options - MSN
10 Biggest Biotechnology Companies - Investopedia
Sumitomo Mitsui Trust Group Inc. Has $32.06 Million Stock Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
BioMarin's VOXZOGO Shows Remarkable Height Gains in 452-Child Achondroplasia Study | BMRN Stock News - StockTitan
Comgest Global Investors S.A.S. Trims Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
Los Angeles Capital Management LLC Acquires New Holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
BioMarin stock touches 52-week low at $65.23 amid challenges - Investing.com India
BioMarin Pharmaceutical (NASDAQ:BMRN) Hits New 1-Year Low on Insider Selling - MarketBeat
BioMarin Pharmaceutical (NASDAQ:BMRN) Now Covered by Analysts at Wolfe Research - MarketBeat
Biomarin pharmaceutical's CTO sells $350k in stock By Investing.com - Investing.com Nigeria
Biomarin pharmaceutical's CTO sells $350k in stock - Investing.com India
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Not Flying Under The Radar - Simply Wall St
WCM Investment Management LLC Has $1.20 Million Stock Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
abrdn Life Sciences Investors declares $0.50 dividend - MSN
Principal Financial Group Inc. Sells 191,421 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
Biomarin Pharmaceutical Inc Stock (BMRN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.05%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):